NasdaqGM:RLAYBiotechs
Assessing Relay Therapeutics (RLAY) Valuation After New ReDiscover Trial Data And FDA Breakthrough Status
Relay Therapeutics (RLAY) is back in focus after releasing new Phase 1/2 ReDiscover trial data for zovegalisib plus fulvestrant in PI3Ka-mutated, HR+/HER2- metastatic breast cancer, supporting its selected Phase 3 dosing regimen.
See our latest analysis for Relay Therapeutics.
The latest trial update comes after a sharp move in the stock, with a 1 day share price return of negative 5.14% and a 30 day share price return of negative 6.43%. However, a 1 year total shareholder return of 266.41%...